Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8766975 | 0.84 | ADRA1B (0.44) | KMT2AMEN1ADRA1BNPC1RAB9A | |
| SCHEMBL8772451 | 0.79 | LMNA (0.40) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL8772367 | 0.72 | LMNA (0.43) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL10875798 | 0.72 | ADRA1B (0.61) | KMT2AMEN1ADRA1BNPC1RAB9A | |
| SCHEMBL11513541 | 0.70 | NPC1 (0.58) | KMT2AMEN1NPC1RAB9ASLC6A3 | |
| SCHEMBL7083850 | 0.67 | PKM (0.39) | KMT2AMEN1NPC1RAB9ASLC6A2 | |
| SCHEMBL8766682 | 0.67 | MEN1 (0.46) | KMT2AMEN1ADRA1BNPC1RAB9A | |
| SCHEMBL8772426 | 0.66 | TRPA1 (0.41) | — | |
| SCHEMBL7389188 | 0.66 | L3MBTL1 (0.73) | KMT2AMEN1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4036783 | 0.66 | PKM (0.57) | KMT2AMEN1NPC1RAB9ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0799200-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |